Literature DB >> 31214919

Fresh osteochondral grafting in the United States: the current status of tissue banking processing.

Brett Goodfriend1, Anthony A Essilfie1, Ian A Jones2, C Thomas Vangsness3,4.   

Abstract

The use of musculoskeletal allografts has become increasingly popular among surgeons. The purpose of this review is to highlight the procurment and delievery process of fresh osteochondral allografts in the United States. The four distributors of fresh osteochondral allografts in the United States were contacted. Surveys containing quantitative and qualitative sections concerning the procurement and processing of osteochondral allograft tissue were obtained. Our results showed an average of 13 ± 4.24 years of experience with osteochondral allografts. The average donor age ranged from 13.5 ± 3 to 37.5 ± 5 years, with an average age of 27 ± 2.83 years. All donors were between ages 12 and 45 years old. The percentage of screened donors that were accepted for allograft transplant was consistent at 70-75% for 3 out of the 4 tissue banks. The percentage of grafts that expire without implantation ranged from 20% to 29%. Maximum shipping time varied between 24 and 96 hours. Each tissue bank used its own proprietary storage medium. The time from donor death to the harvest of allograft tissue was < 24 hours. The most commonly requested osteochondral allograft tissue for all banks was the medial femoral condyle. The market share of fresh allografts is as follows: Joint Restoration Foundation (JRF) 59.9%, Muskuloskeletal Transplant Foundation (MTF) 15.3%, LifeNet Health (LN) 14.5%, and Regeneration Technology Incorporated (RTI) 10.2%, with approximately 4700 fresh allografts distributed in 2018. This compiled data from the four tissue banks that supply fresh osteochondral allograft in the United States  provides important background information for patients and orthopaedic surgeons.

Entities:  

Keywords:  Allograft; Banking; Osteochondral; Tissue; Transplant

Mesh:

Year:  2019        PMID: 31214919     DOI: 10.1007/s10561-019-09768-5

Source DB:  PubMed          Journal:  Cell Tissue Bank        ISSN: 1389-9333            Impact factor:   1.522


  6 in total

1.  The potential of radiation sterilized and banked tissue allografts for management of nuclear casualties.

Authors:  Rita Singh; Antaryami Singh
Journal:  Cell Tissue Bank       Date:  2021-07-31       Impact factor: 1.522

2.  Vitrification of particulated articular cartilage via calculated protocols.

Authors:  Kezhou Wu; Nadia Shardt; Leila Laouar; Janet A W Elliott; Nadr M Jomha
Journal:  NPJ Regen Med       Date:  2021-03-19

3.  Histological and Inflammatory Cytokine Analysis of Osteochondral Lesions of the Talus After Failed Microfracture: Comparison With Fresh Allograft Controls.

Authors:  Richard M Danilkowicz; Nicholas B Allen; Nate Grimm; Dana L Nettles; James A Nunley; Mark E Easley; Samuel B Adams
Journal:  Orthop J Sports Med       Date:  2021-10-29

4.  Osteochondral Allograft for Unsalvageable Osteochondritis Dissecans in the Skeletally Immature Knee.

Authors:  Breann Tisano; Henry B Ellis; Chuck Wyatt; Philip L Wilson
Journal:  Orthop J Sports Med       Date:  2022-02-11

5.  Cartilage Assessment Requires a Surface Characterization Protocol: Roughness, Friction, and Function.

Authors:  M Gabriela Espinosa; Gaston A Otarola; Jerry C Hu; Kyriacos A Athanasiou
Journal:  Tissue Eng Part C Methods       Date:  2021-04       Impact factor: 3.056

6.  Patient-specific metal implants for focal chondral and osteochondral lesions in the knee; excellent clinical results at 2 years.

Authors:  Johannes Holz; Tim Spalding; Tarek Boutefnouchet; Pieter Emans; Karl Eriksson; Mats Brittberg; Lars Konradsen; Clemens Kösters; Peter Verdonk; Magnus Högström; Martin Lind
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2020-10-06       Impact factor: 4.114

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.